ArticleInternational urology and nephrology2026
The volume of Gleason grade group 1 prostate cancer at biopsy predicts unfavorable pathology but not upgrading after radical prostatectomy.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FIB-4 is associated with Gleason grade group upgrading after radical prostatectomy: a comparison of inflammatory and AST/ALT-based indices in active surveillance-eligible men.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate whether volume of Gleason grade group 1 (GGG1) prostate cancer at prostate biopsy predicts unfavorable pathologic findings after radical prostatectomy (RP).
methodsWe retrospectively reviewed clinical and pathologic data from patients with biopsy-confirmed GGG1 prostate cancer and prostate-specific antigen < 20 ng/mL who underwent RP at our institution between May 2014 and May 2023. The percentage of positive biopsy cores (PPC) was defined as the number of cancer positive cores divided by the total number of cores at biopsy. The primary outcome was unfavorable pathology at RP, defined as ≥ GGG3, and/or pT3/4, and/or pN1. Gleason upgrading (≥ GGG2) and biochemical recurrence after RP were also evaluated. Multivariable logistic regression analyses were performed to assess the association between PPC and the risk of unfavorable pathology and Gleason upgrading.
resultsA total of 213 patients were analyzed. Median PPC was 17.0%. Unfavorable pathology was observed in 41.8%, while 53.1% had Gleason upgrading. PPC ≥ 17% was significantly associated with unfavorable pathology (odds ratio = 1.02; p = 0.030), but not with Gleason upgrading (odds ratio = 1.01; p = 0.189). The 5-year biochemical recurrence-free survival was 98.2% for PPC < 17% and 97.8% for PPC ≥ 17%, with no significant difference between the groups (log-rank p = 0.417).
conclusionHigher PPC was associated with unfavorable pathologic outcomes, but not with upgrading or recurrence, in biopsy-confirmed GGG1 prostate cancer patients treated with RP.
Indexed as
Identifiers
40593300What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.